23 / 25
Page 61
conferenceseries
.com
Volume 8
Journal of Gastrointestinal & Digestive System
ISSN: 2161-069X
Bariatric Surgery 2018 & Gastro 2018
March 15-16, 2018
JOINT EVENT
12
th
Global Gastroenterologists Meeting
3
rd
International Conference on Metabolic and Bariatric Surgery
&
March 15-16, 2018 Barcelona, Spain
Patient stratification and precision medicine in pancreatic cancer: A gene blood-signature for gemcitabine
treatment
David Piquemal, Fabien Pierrat, Roman Bruno
and
Florian Noguier
ACOBIOM, France
P
ancreatic cancer (PC) kills 98% of those it afflicts and is one of the most lethal cancers worldwide: patients diagnosed with PC
have a poor prognosis partly because the cancer usually causes no symptoms early on, leading to metastatic disease at the time
of diagnosis. The high mortality rate is partly due to the difficulty to diagnose and due to the lack of stratified patients to effective
treatments. The capability of biomarkers to improve treatment and to reduce healthcare costs is potentially greater than in any other
area of current medical research. Otherwise, healthcare stakeholders are facing two major issues: the reduction of global healthcare
system expenditures and the growing need to improve the efficiency of therapies. Diagnostics are one of the most efficient solutions
to respond to these needs by supporting physicians in the selection of the best treatment. In without a priori analysis and from a
whole blood collection, from clinical trial phase III and based on a high throughput analysis of NGS data using the proprietary
ACOBIOM genomics platform (Big Data system dedicated to Biomarker discovery), we identified a set of genes in a pre-discovery
phase. Using Real-Time PCR, candidate genes were selected for test significance and a Gene Expression-based Score was established.
ACOBIOM developed a new
In Vitro
diagnostic for patient stratification based on molecular analysis. The GemciTest® assay is an IVD
associated with gemcitabine drug in PC treatment. GemciTest® is currently a prototype in an operational environment through a 15
Clinician Peer Network. This IVD is a quantitative real-time PCR assay and is intended to quantitatively aid in the determination of
high probability Progression- Free Survival and Overall Survival rates of patients diagnosed with pancreatic cancer and treated with
gemcitabine as first-line therapy. In this context, ACOBIOM is always looking for new partnerships, public or private, the right way
to really open the opportunity to develop safe/better solution in PC for the patient (Bench-to-Bedside), assisting physicians in routine
patient care.
Recent Publications
1.
Carlini F et al. (2017) Bronchial epithelial cells from asthmatic patients display less functional HLA-G isoform expression.
Front. Immunol. 8:6.
2.
Deplanque G et al. (2015) A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment
of advanced pancreatic cancer. Ann Oncol. 26(6):1194-1200.
3.
Assou S et al. (2013) MicroRNAs: new candidates for the regulation of the human cumulus-oocyte complex. Hum. Reprod.
28(11):3038-3049.
4.
Bou Samra E et al. (2012) New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes
of chronic myelomonocytic leukaemia patients. Br. J Haematol. 157(3):347-356.
5.
Cheval L et al. (2011) Atlas of gene expression in the mouse kidney: new features of glomerular parietal cells. Physiol
Genomics. 43(3):161-173.
David Piquemal et al., J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C1-064